Sab biotherapeutics, inc.SABSW.US Overview
US StockHealthcare
(No presentation for SABSW)
SABSW Overall Performance
SABSW AI Analysis & Strategy
SABSW Recent Performance
-
Sab biotherapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
SABSW PowerScanner
SABSW Key Information
SABSW Valuation Metrics
SABSW Earnings Table
SABSW Profile
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.